An evaluation of a real-world, multi-disciplinary, treatment-free remission programme for patients with Chronic Myeloid Leukaemia
Journal of Oncology Pharmacy Practice
Published online on October 09, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionThe management of chronic myeloid leukaemia (CML) has been revolutionized by the introduction of imatinib and other tyrosine kinase inhibitors (TKIs). Despite excellent efficacy, patient quality of life is often negatively affected by TKI side ...
IntroductionThe management of chronic myeloid leukaemia (CML) has been revolutionized by the introduction of imatinib and other tyrosine kinase inhibitors (TKIs). Despite excellent efficacy, patient quality of life is often negatively affected by TKI side ...